NASDAQ:ENGN enGene Q3 2025 Earnings Report $5.00 +0.13 (+2.67%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$4.97 -0.03 (-0.60%) As of 06:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast enGene EPS ResultsActual EPSN/AConsensus EPS -$0.51Beat/MissN/AOne Year Ago EPSN/AenGene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AenGene Announcement DetailsQuarterQ3 2025Date9/10/2025TimeBefore Market OpensConference Call DateTuesday, September 9, 2025Conference Call Time9:30AM ETConference Call ResourcesEarnings HistoryCompany Profile enGene Earnings HeadlinesEx-pilot accused of trying to cut a passenger flight’s engines reaches plea deals: lawyerSeptember 5 at 2:44 AM | msn.comEx-pilot accused of trying to cut a passenger flight’s engines reaches plea deals, his lawyer saysSeptember 5 at 2:44 AM | yahoo.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the most famous companies in the world by 2030.September 5 at 2:00 AM | The Oxford Club (Ad)Every 2025 Ford Pickup Engine Ranked By Power OutputSeptember 4 at 6:34 AM | msn.comThe Honda Engine Scam: Are You Driving One of the 1.4 Million Defective Vehicles?September 4 at 6:34 AM | msn.com5 Of The Best-Sounding Four-Cylinder Engines Of All TimeSeptember 4 at 2:27 AM | msn.comSee More enGene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email. Email Address About enGeneenGene (NASDAQ:ENGN), Inc. is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity. Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages. Each EDV is surface‐decorated with bispecific antibodies designed to bind specific tumor antigens, enabling selective accumulation in malignant tissues. The platform supports a range of payloads—from chemotherapeutic agents to nucleic acid–based molecules—providing versatility in addressing diverse tumor profiles. Headquartered in San Diego, California, enGene collaborates with leading academic and research institutions to propel its pipeline forward. The company is overseen by a management team with deep expertise in gene and cell therapy development, drug delivery systems, and oncology research, positioning enGene to tackle the complex challenges inherent in targeted cancer therapy.Written by Jeffrey Neal JohnsonView enGene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Affirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 Outlook Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
